Risk factor of second primary gynecological malignancy among women with breast cancer surgery

doi:10.3969/j.issn.1006-7795.2017.01.019

Abstract

Abstract: Objective To investigate the risk factor of second primary gynecological malignancy among women diagnosed with breast cancer.Methods In order to examine these factors in women with breast cancer who develop subsequentgynecological malignancy, a case-control study was performed. All the patients and control cases were enrolled from Beijing Chaoyang Hospital, Capital Medical University with the case vs control ratio of 1:4. Information concerning possible risk factors were extracted from hospital records and compared with matched controls. χ² and multivariate Logistic regression analysis were performed with SPSS18.0 statistical software for data statistics. Results Among the cases followed, 12 cases of ovarian cancer and 12 cases of endometrial cancer were diagnosed. Univariate analysis suggested that factors such as menarche early than 13 years (OR=6.5,95% CI:2.37-27.81), family history of cancer(OR=3.57,95% CI:1.27-10.06),family history of breast and/or gynecological cancer(OR=5.13,95% CI:1.47-17.92),diabetes mellitus(OR=2.12,95% CI:1.32-12.70) were possibly connected with a significantincreased risk of subsequent gynecological malignancy,while endocrine therapy(OR=0.29,95% CI:0.11-0.78), gynecologic examination termly(OR=0.33,95% CI:0.12-0.86) were significantdecreased risk of subsequent gynecological malignancy. Further multivariate Logistic regression analysis showed that heredity of breast and/or gynecological malignancy (P=0.003, OR=5.951), the early menarche age (P=0.000, OR=9.909), diabetes (P=0.010, OR=9.842) are risk factors of the breast cancer subsequent gynecological malignancy. Gynecological examination termly after breast cancer (P=0.037, OR=0.268) was a protective factor.Conclusion Patients of breast cancer with heredity for breast and/or gynecological cancer, early menarche age, suffered from diabetes have a higher risk of subsequent gynecological malignancy.It was recommended that breast cancer surveillance should including gynecologic examination termly which may be a protective factor from subsequent gynecological malignancy.

Key words: breast cancer, endometrial cancer, ovarian cancer, risk factors

CLC Number:

Liu Chen, Wu Long, Jiang Hongchuan, Li Jie, Liu Jun, Wang Shuzhen. Risk factor of second primary gynecological malignancy among women with breast cancer surgery[J]. Journal of Capital Medical University, 2017, 38(1): 92-96.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.01.019

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I1/92

References

[1] Torre L A, Bray F, Siegel R L,et al. Global cancer statistics,2012[J].CA Cancer J Clin, 2015, 65(2):87-108.
[2] Schonfeld S J, Berrington de Gonzalez A, Visvanathan K,et al. Declining second primary ovarian cancer after first primary breast cancer[J]. J ClinOncol, 2013,31(6):738-743.
[3] Molina-Montes E, Pollán M, Payer T, et al. Risk of second primary cancer among women with breast cancer:a population-based study in Granada[J]. Gynecol Oncol,2013,130(2):340-345.
[4] Woodruff J D, Solomon D, Sullivant H. Multifocal disease in the upper genital canal[J]. Obstet Gynecol, 1985, 65(5):695-698.
[5] Berkowitz Z, Rim S H, Peipins L A. Characteristics and survival associated with ovarian cancer diagnosed as first cancer and ovarian cancer diagnosed subsequent to a previous cancer[J]. Cancer Epidemiol, 2011, 35(2):112-129.
[6] Bergfeldt K, Rydh B, Granath F, et al. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer:a population-based cohort study[J]. Lancet, 2002, 360(9337):891-894.
[7] Pike M C. Reducing cancer risk in women through lifestyle-mediated changes in hormone levels[J]. Cancer Detect Prev,1990, 14(6):595-607.
[8] Franceschi S, La Vecchia C, Booth M, et al. Pooled analysis of 3 European case-control studies of ovarian cancer:II. Age at menarche and at menopause[J]. Int J Cancer, 1991, 49(1):57-60.
[9] Takahashi H, Behbakht K, McGovern P E, et al. Mutation analysis of the BRCA1 gene in ovarian cancers[J]. Cancer Res,1995, 55(14):2998-3002.
[10] Russell S E, Hickey G I, Lowry W S, et al. Allele loss from chromosome 17 in ovarian cancer[J].Oncogene, 1990, 5(10):1581-1583.
[11] Yang W, Lu J, Weng J, et al.Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12):1090-1101.
[12] 赵群, 张凇文, 王涛,等. 北京地区卵巢恶性肿瘤发病相关因素分析[J]. 实用妇产科杂志,2010,26(2):111-113.
[13] Nasu K, Takai N, Nishida M, et al. Tumorigenic effects of tamoxifen on the female genital tract[J]. Clin Med Pathol,2008, 1:17-34.
[14] 李琳,王淑珍,张震宇,等. 乳腺癌病人三苯氧胺治疗后妇科良性疾患的随访研究[J].中华医学杂志,2010,90(25):1735-1738.
[15] 郭红霞,王淑珍,崔秀平.乳腺癌病人发生妇科肿瘤情况的随访研究[J].中国妇幼卫生杂志,2013,4(3-4):26-27.
[16] Deligdisch L, Kalir T, Cohen C J, et al. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer[J]. Gynecol Oncol, 2000, 78(2):181-186.